Li Gan

Li Gan

Auto-generated profile, based on publicly available information

Li Gan

Department of Laboratory Medicine, West China Hospital of Stomatology, Sichuan University 3 , Chengdu 610041, China

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 September 2023 in Phytomedicine
Verified
Journal Article
Open access
ZLZhuo-Yao Li
Zhuo-Yao Li
YDYu-Xiang Dai
Yu-Xiang Dai
ZWZi-Ming Wu
Zi-Ming Wu
GLGan Li
Gan Li
PPPei-Min Pu
Pei-Min Pu
MYMin Yao
Min Yao
Cervical spondylotic myelopathy (CSM) is a degenerative pathology that affects both upper and lower extremity mobility and sensory function, causing significant pressure on patients and society. Prior research has suggested that ginsenosides may have neuroprotective properties in central nervous system diseases. However, the efficacy and mechanism of ginsenosides for CSM have yet to be investigated. This study aims to analyze the composition of ginsenosides using UPLC-MS, identify the underlying mechanism of ginsenosides in treating CSM using network pharmacology, and subsequently confirm the efficacy and mechanism of ginsenosides in rats with chronic spinal cord compression. UPLC-Q-TOF-MS was utilized to obtain mass spectrum data of ginsenoside samples. The chemical constituents of the samples were analyzed by consulting literature reports and relevant databases. Ginsenoside and CSM targets were obtained from the TCMSP, OMIM, and GeneCards databases. GO and KEGG analyses were conducted, and a visualization network of ginsenosides-compounds-key targets-pathways-CSM was constructed, along with molecular docking of key bioactive compounds and targets, to identify the signaling pathways and proteins associated with the therapeutic effects of ginsenosides on CSM. Chronic spinal cord compression rats were intraperitoneally injected with ginsenosides (50 mg/kg and 150 mg/kg) and methylprednisolone for 28 days, and motor function was assessed to investigate the therapeutic efficacy of ginsenosides for CSM. The expression of proteins associated with TNF, IL-17, TLR4/MyD88/NF-κB, and NLRP3 signaling pathways was assessed by immunofluorescence staining and western blotting. Using UPLC-Q-TOF-MS, 37 compounds were identified from ginsenoside samples. Furthermore, ginsenosides-compounds-key targets-pathways-CSM visualization network indicated that ginsenosides may modulate the PI3K-Akt signaling pathway, TNF signaling pathway, MAPK signaling pathway, IL-17 signaling pathway, Toll-like receptor signaling pathway and Apoptosis by targeting AKT1, TNF, MAPK1, CASP3, IL6, and IL1B, exerting a therapeutic effect on CSM. By attenuating neuroinflammation through the TNF, IL-17, TLR4/MyD88/NF-κB, and MAPK signaling pathways, ginsenosides restored the motor function of rats with CSM, and ginsenosides 150 mg/kg showed better effect. This was achieved by reducing the phosphorylation of NF-κB and the activation of the NLRP3 inflammasome. The results of network pharmacology indicate that ginsenosides can inhibit neuroinflammation resulting from spinal cord compression through multiple pathways and targets. This finding was validated through in vivo tests, which demonstrated that ginsenosides can reduce neuroinflammation by inhibiting NLRP3 inflammasomes via multiple signaling pathways, additionally, it should be noted that 150 mg/kg was a relatively superior dose. This study is the first to verify the intrinsic molecular mechanism of ginsenosides in treating CSM by combining pharmacokinetics, network pharmacology, and animal experiments. The findings can provide evidence for subsequent clinical research and drug development.

19 July 2024 in Applied Physics Reviews
Verified
Journal Article
Closed access
PDF file
Shan LiuShan Liu
Shan Liu
XLXue Li
Xue Li
LGLi Gan
Li Gan
SLSutong Liu
Sutong Liu
HLHongzhi Luo
Hongzhi Luo
Chenzhong LiChenzhong Li
Chenzhong Li
Real-time health monitoring and precision treatment are important in the biomedical field. Researchers have focused on unique gadgets with peculiar functions, which have emerged from the merging of electronic components with biological systems. Because implantable bioelectronics can sense bodily information or elicit bodily reactions in living creatures from sites outside the body, they are becoming helpful and promising remedies for a variety of ailments. Carbon materials are more suitable than other materials for the manufacture of implantable medical electronics due to their excellent biocompatibility, fatigue resistance, and low specific gravity. Therefore, carbon materials can apply to a wide range of implantable drug delivery devices, biosensors, therapeutic stimulators, and energy storage and play irreplaceable roles in neurological, cardiovascular, gastrointestinal, and locomotor systems, among others. This review aims to offer researchers insight into carbon-based implantable bioelectronics in the biomedical field. Initially, various types of carbon materials were introduced. Subsequently, it delves into carbon-based implantable bioelectronics from four perspectives: implantable actuators, biosensors, drug delivery systems, and power supplies. Furthermore, we anticipate the future direction and potential applications of carbon-based implantable bioelectronics. Given the evolving field of nanotechnology and bioelectronics, we are optimistic that these devices will foster significant breakthroughs and innovations in the biomedical sector. Ultimately, this review aims to assist researchers in navigating the choices and directions of carbon-based implantable bioelectronics, thereby promoting the advancement of the biomedical field and contributing positively to the health and welfare of humankind.

1 April 2019 in OncoTargets and Therapy
Verified
Journal Article
Open access
PDF file
HTHong Tan
Hong Tan
LGLi Gan
Li Gan
XFXiaoming Fan
Xiaoming Fan
LLLimin Liu
Limin Liu
SLShan Liu
Shan Liu
Background: Increasing evidence has identified circular RNAs (circRNAs) as ideal molecular biomarkers for cancer diagnosis, therapy, and prognosis. However, the overall diagnostic efficiency of circRNAs remains unclear. Thus, this meta-analysis aimed to comprehensively evaluate the diagnostic accuracy of circRNA expression profiles for cancer. Methods: A literature search of online databases was conducted to identify all eligible studies. The quality of the studies was assessed using the Quality Assessment of Diagnostic Accuracy Studies 2 tool. All statistical analyses were executed using STATA 14.0, Meta-DiSc 1.4, and Review Manager 5.2 software. Results: A total of 32 studies, involving 2,400 cases and 2,295 controls, were included in the diagnostic meta-analysis. The pooled sensitivity, specificity, positive likelihood ratio, negative likelihood ratio, diagnostic odds ratio, and area under the curve were 0.79 (95% CI: 0.73–0.84), 0.73 (95% CI: 0.67–0.79), 2.9 (95% CI: 2.5–3.5), 0.29 (95% CI: 0.24–0.36), 10 (95% CI: 8–13), and 0.83 (95% CI: 0.79–0.86), respectively. The overall analysis suggested that circRNAs are useful diagnostic biomarkers for cancer. Subgroup analysis indicated that plasma samples had a better diagnostic performance than cancer tissue samples for cancer detection. Studies involving ≥100 cases or gastric cancer showed higher sensitivities than those including <100 cases or other cancers. Conclusion: This meta-analysis revealed that circRNAs were significantly correlated with cancer diagnosis. In addition, circRNAs had good diagnostic accuracy and might serve as effective diagnostic biomarkers for cancer.

1 August 2020 in Clinica Chimica Acta
Verified
Journal Article
Closed access
LGLi Gan
Li Gan
CYChen Yang
Chen Yang
YSYi Shu
Yi Shu
FLFang Liu
Fang Liu
RSRuiting Sun
Ruiting Sun
JLJing Li
Jing Li

1 November 2017
Verified
Book Chapter
Closed access
LGLi Gan
Li Gan
Neurodegenerative dementias, including Alzheimer’s disease (AD), Parkinson’s disease (PD) and Frontotemporal dementia (FTD), pose enormous challenges for our aging society. Genetic and mechanistic studies have revealed common molecular and cellular pathways, including imbalanced proteostasis and aberrant innate immune responses. Key pathogens in AD, PD, and FTD accumulate and spread from one brain region to another, resulting in network dysfunction and cognitive decline. These diseases are multifactorial, caused by interactions among multiple genetic, epigenetic, and environmental factors and pathways. Combination therapies that target multiple pathways may also be needed to stop or delay the dementing conditions in neurodegenerative dementias.